TB-500
Tissue and Repair Signalling
£28.00per vial
TB-500 is a synthetic peptide based on the actin-binding region of thymosin beta-4, a protein involved in actin sequestration, cell migration, and angiogenesis. Laboratory work examines it in wound-repair, tendon and ligament, corneal, and neovascularisation models, with emphasis on cytoskeletal reorganisation.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
TB-500 cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 889 g/mol
- Sequence
- Ac-LKKTETQ-OH
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for TB-500, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 889 g/mol
- Sequence
- Ac-LKKTETQ-OH
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- TB5602
Molecular weight source: PubChem CID 62707662, N-acetyl LKKTETQ.
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 97.9% |
| Identity | Mass spectrometry | Confirmed |
TB5602 · 2026-05-19
§04Compound details
TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4, the LKKTETQ motif, acetylated at the N-terminus. Thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells, and the fragment is studied for the same actin-binding behaviour in isolation. Its mechanism is described in the literature as receptor-independent, which distinguishes it structurally from the receptor-agonist compounds catalogued elsewhere in this reference.
Preclinical investigations have examined TB-500 in actin polymerisation assays, endothelial cell migration models, and angiogenesis frameworks. Published work also references its influence on inflammatory signalling and on cellular differentiation processes under controlled conditions. Research contexts include tendon and ligament repair models, corneal and dermal wound models, and cardiac tissue remodelling models.
TB-500 is catalogued here as a reference compound for laboratory research. The findings above are drawn from animal and cell-culture studies. No therapeutic, diagnostic, or clinical conclusion is drawn from them, and none should be inferred.
TB-500 is listed as a pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which for this compound also separates the acetylated seven-residue fragment from the full 43-residue parent protein that shares its name in common usage. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue.
Research Use Only
TB-500 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about TB-500. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for TB-500 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
TB-500 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4, the LKKTETQ motif, acetylated at the N-terminus. Thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells, and the fragment is studied for the same actin-binding behaviour in isolation. Its mechanism is described in the literature as receptor-independent, which distinguishes it structurally from the receptor-agonist compounds catalogued elsewhere in this reference.
Preclinical investigations have examined TB-500 in actin polymerisation assays, endothelial cell migration models, and angiogenesis frameworks. Published work also references its influence on inflammatory signalling and on cellular differentiation processes under controlled conditions. Research contexts include tendon and ligament repair models, corneal and dermal wound models, and cardiac tissue remodelling models.
TB-500 is catalogued here as a reference compound for laboratory research. The findings above are drawn from animal and cell-culture studies. No therapeutic, diagnostic, or clinical conclusion is drawn from them, and none should be inferred.
Analysis and Documentation
TB-500 is listed as a pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which for this compound also separates the acetylated seven-residue fragment from the full 43-residue parent protein that shares its name in common usage. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue.
Compliance Notice
Research Use Only
TB-500 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about TB-500. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for TB-500 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
TB-500 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§06Questions
No. TB-500 is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Actin binding, cytoskeletal reorganisation, and cell migration in laboratory wound-repair and angiogenesis models. Findings are preclinical.
It is a synthetic peptide based on the actin-binding region of thymosin beta-4, the LKKTETQ motif, rather than the full 43-amino-acid protein.
Pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised powder and needs no preparation before laboratory use.
HPLC for purity and mass spectrometry for identity, on every batch, before it is listed. Mass spectrometry also separates the seven-residue fragment from the full parent protein. No further assay is claimed.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
